Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 9 · below the Ichimoku cloud · RSI 33 · MACD above its signal · 5% above its 52-week low
| 1,443.36 | 52-week high | +110080.15% |
| 2.08 | Previous month high | +58.78% |
| 1.59 | Previous week high | +21.37% |
| 1.54 | R3 (classic) | +17.94% |
| 1.49 | R2 (classic) | +13.74% |
| 1.47 | Previous month low | +12.37% |
| 1.43 | Previous day high | +9.54% |
| 1.40 | R1 (classic) | +6.87% |
| 1.34 | Pivot | +2.67% |
| 1.31 | Price now | |
| 1.29 | Previous day low | −1.53% |
| 1.25 | S1 (classic) | −4.20% |
| 1.25 | Previous week low | −4.35% |
| 1.25 | 52-week low | −4.35% |
| 1.20 | S2 (classic) | −8.40% |
| 1.11 | S3 (classic) | −15.27% |
None of the 29 investors followed here reported a position in ZCMD in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ZCMD trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 20, 2026 | Yang WeiguangChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 2.50M | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 6.7 | -54.8 | 2.5 | 21.3 | -92.3 | -93.2 | 7.6 | -22.4 | -1.6 | -24.1 | −99.8% | ||
| 2025 | -13.6 | -12.9 | 4.9 | -7.8 | -1.7 | 4.3 | -15.1 | -2.5 | 14.9 | -40.6 | -2.5 | -32.4 | −72.2% |
| 2024 | -11.7 | 0.0 | -56.8 | 19.6 | -22.0 | 5.6 | -14.4 | 23.9 | 75.7 | -45.9 | 0.8 | 20.9 | −53.8% |
| 2023 | -0.8 | -11.4 | 21.8 | -8.1 | -7.1 | 14.3 | 1.2 | -4.5 | -5.2 | -4.6 | -8.9 | -63.3 | −69.5% |
| 2022 | -9.0 | 6.8 | -21.4 | -8.1 | 1.6 | 2.0 | -2.0 | -7.9 | -1.7 | -3.5 | 9.9 | -5.8 | −35.4% |
| 2021 | 7.6 | 4.4 | 3.7 | -8.1 | -3.3 | 4.5 | -8.7 | 1.8 | -4.1 | 1.8 | 15.0 | -7.3 | +4.7% |
| 2020 | -37.3 | -8.6 | -6.2 | 3.8 | 10.6 | -15.8 | -15.1 | -0.8 | 6.7 | -6.8 | −56.5% |
TimeframesThe daily, weekly and monthly trends are down; the hourly is steadying, a bounce inside them.
pulling back under the 21 EMA
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
No analyst coverage for this instrument.
Zhongchao Inc. provides healthcare information, education, and training services to healthcare professionals under their MDMOOC brand in the People's Republic of China. It operates through two segments, MDMOOC services, and Sales of Patented Drugs. The company offers patient management services in the tumor and rare diseases field, internet healthcare services, and pharmaceutical services, and operates an online information platform. It also provides online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes on popular medical topics, interactive case studies, academic conferences and workshops, continuing education courses, and articles and short videos with educational healthcare content. The company offers its services through its MDMOOC online platform, such as the MDMOOC mobile app, MOOC Medical WeChat subscription account, and MDMOOC website, and patient management services through an IT system under the Zhongxun brand, WeChat mini program, and Zhongxin Health WeChat mini program. It serves pharmaceutical enterprises and non-profit organizations, including medical associations, medical institutions, medical journals, medical foundations, and hospitals, as well as healthcare professionals, nurses, and doctors. Zhongchao Inc. was founded in 2012 and is headquartered in Shanghai, China.